Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures: The Women's Health Initiative Randomized Trial

JAMA

Volumn 290, Issue 13, 2003, Pages 1739-1748

  Anderson, Garnet L ^a   Judd, Howard L ^c   Kaunitz, Andrew M ^d   Barad, David H ^e   Beresford, Shirley A A ^a,b   Pettinger, Mary ^a   Liu, James ^f   McNeeley, S Gene ^g   Lopez, Ana Maria ^h  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOMETRIUM CANCER; ETHNOLOGY; FAMILY HISTORY; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INFERTILITY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; MULTICENTER STUDY; ORAL CONTRACEPTION; OVARIECTOMY; OVARY CANCER; PAPANICOLAOU TEST; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; STATISTICAL ANALYSIS; UNITED STATES; UTERINE CERVIX CANCER; VAGINA BLEEDING; BIOPSY; ENDOMETRIUM; ENDOMETRIUM TUMOR; ESTROGEN THERAPY; FEMALE GENITAL TRACT TUMOR; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; UTERINE CERVIX TUMOR; VAGINA SMEAR;

AGED; BIOPSY; DOUBLE-BLIND METHOD; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; OVARIAN NEOPLASMS; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 0141593565     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.13.1739     Document Type: Article

References (35)

1. Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997;89:1110-1116.
2. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999; 91:1131-1137.
3. Hill DA, Weiss NS, Beresford SAA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol. 2000; 183:1456-1461
4. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321-333.
6. Kaunitz AM, Masciello A, Ostrowski M, Rovira EZ. Comparison of endometrial biopsy with the endometrial pipelle and vabra aspirator. J Reprod Med. 1988; 33:427-430.
7. Stovall TG, Photopulos GJ, Poston WM, Ling FW, Sandles LG. Pipelle endometrial sampling in patients with known endometrial carcinoma. Obstet Gynecol. 1991;77:954-956.
8. Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abmormalites. JAMA. 1998; 280:1510-1517.
9. Percy C, Van Holten V, Muir C, eds. International Classification of Diseases for Oncology, 2nd Edition. Geneva, Switzerland: World Health Organization; 1990
10. The SEER Program Code Manual, Revised Edition. Bethesda, Md: Cancer Statistics Branch, National Cancer Institute; 1992.
11. Freedman LS, Anderson GL, Kipnis V, et al. Approaches to monitoring the results of long-term disease prevention trials. Control Clin Trials. 1996;17: 509-525.
12. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA. 1996;275:370-375.
13. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER)*Stat Database (1973-2000). Available at: http://www.seer.cancer .gov. Accessed April 17, 2003.
14. Weiss NS, Lyon JL, Rishnamurthy S, Dietert SE, Liff JM, Daling J. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst. 1982;68:95-98.
15. Booth M, Beral V, Smith P. Risk factors for ovarian cancer. Br J Cancer. 1989;60:592-598.
16. Whittemore AS. Personal characteristics relating to risk of invasive epithelial ovarian cancer in older women in the United States. Cancer. 1993;72:558-565.
17. Purdie D, Green A, Bain C, et al. Reproductive and other factors and risk of epithelial ovarian cancer. Int J Cancer. 1995;62:678-684.
18. Risch HA. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol. 1996; 63:254-257.
19. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA. 2001;285:1460-1465.
20. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002;288:334-341.
21. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish Women. J Natl Cancer Inst. 2002;94:497-504.
22. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998; 90:1774-1786.
23. Gardner WU. Tumorigenesis in transplanted irradiated and non-irradiated ovaries. J Natl Cancer Inst. 1961;26:829-854.
24. Stadel BV. The etiology and prevention of ovarian cancer. Am J Obstet Gynecol. 1975;123:772-774.
25. Cramer DW, Welch WR. Determinants of ovarian cancer risk, II: inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71:717-721.
26. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91:1459-1467.
27. Cramer DW, Xu H. Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Ann Epidemiol. 1995;5:310-314
28. Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia? Lancet. 1971;2:163.
29. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol. 2000;152:233-241.
30. Rodriguez GC, Walmer DK, Cline M. Effect of progestin on the ovarian epithelim of macaques. J Soc Gynecol Investig. 1998;5:271-276.
31. Woodruff JD, Pickar JH, et al. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol. 1994;170:1213-1223.
32. Speroff L, Rowan J, Symons J, et al. The comparative effect on bone density, endometrium and lipids of continuous hormones as replacement therapy (CHART study). JAMA. 1996;276:1397-1403.
33. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 2002;288:58-66.
34. American College of Obstetricians and Gynecologists. Hormone therapy: questions and answers from ACOG physicians. Available at: http://www.acog.org /from_home/publications/press_releases/nr08-30-02 .cfm. Accessed March 31, 2003.
35. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med. 2002;137:834-839.